- Home
- USIO vs DXR Comparison
USIO vs DXR Comparison
Compare USIO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- DXR
- Stock Information
- Founded
- USIO 1998
- DXR 1970
- Country
- USIO United States
- DXR United States
- Employees
- USIO N/A
- DXR N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- DXR Medical/Dental Instruments
- Sector
- USIO Finance
- DXR Health Care
- Exchange
- USIO Nasdaq
- DXR Nasdaq
- Market Cap
- USIO 50.2M
- DXR 46.9M
- IPO Year
- USIO N/A
- DXR N/A
- Fundamental
- Price
- USIO $1.46
- DXR $11.42
- Analyst Decision
- USIO Strong Buy
- DXR Strong Buy
- Analyst Count
- USIO 1
- DXR 1
- Target Price
- USIO $4.00
- DXR $25.00
- AVG Volume (30 Days)
- USIO 75.7K
- DXR 6.8K
- Earning Date
- USIO 11-05-2025
- DXR 01-01-0001
- Dividend Yield
- USIO N/A
- DXR N/A
- EPS Growth
- USIO N/A
- DXR 3.46
- EPS
- USIO 0.11
- DXR 0.36
- Revenue
- USIO $83,851,606.00
- DXR $66,306.00
- Revenue This Year
- USIO $8.66
- DXR N/A
- Revenue Next Year
- USIO $13.32
- DXR N/A
- P/E Ratio
- USIO $13.74
- DXR $31.70
- Revenue Growth
- USIO 2.05
- DXR N/A
- 52 Week Low
- USIO $1.24
- DXR $6.55
- 52 Week High
- USIO $2.92
- DXR $11.70
- Technical
- Relative Strength Index (RSI)
- USIO 45.46
- DXR 56.80
- Support Level
- USIO $1.44
- DXR $11.37
- Resistance Level
- USIO $1.58
- DXR $11.70
- Average True Range (ATR)
- USIO 0.07
- DXR 0.50
- MACD
- USIO 0.01
- DXR -0.00
- Stochastic Oscillator
- USIO 40.00
- DXR 83.53
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.